Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a procedure called prophylactic amnioinfusion, which aims to reduce the risk of severe bleeding after childbirth, known as postpartum hemorrhage (PPH). PPH can happen when a woman loses a significant amount of blood after delivering a baby, and in some cases, it may require blood transfusions or even surgery. The study focuses on women who are at medium to high risk for PPH and will look at the effectiveness of this procedure in preventing serious complications related to blood loss.

To participate in this trial, women must be pregnant with a single baby and at least 34 weeks along in their pregnancy. They need to be in labor, whether naturally or induced, and meet certain risk criteria set by medical guidelines. However, women who are having twins, scheduled for a cesarean delivery, or have specific health concerns will not be eligible. If chosen to participate, women can expect to receive the amnioinfusion procedure during labor, which involves placing a catheter (a thin tube) into the uterus to help manage fluid levels. This trial is not currently recruiting participants, but it will provide valuable insights into better managing postpartum hemorrhage in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Singletons with a gestational age of 34.0 weeks or more
• • Labor (spontaneous or medical induction)
• • Medium- or High-risk for PPH, as described by American College of Obstetricians and Gynecologists (ACOG)
• Exclusion Criteria:
• • Scheduled cesarean delivery
• • Multiple gestations
• • Delivery at \< 34.0 weeks
• • Contraindication to place intrauterine pressure catheter (e.g. HIV)
• • Incarcerated subjects
• • Major fetal anomalies requiring neonatal surgical intervention
• • Stillbirth on admission